Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 277

1.

Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.

Frey SE, Bernstein DI, Gerber MA, Keyserling HL, Munoz FM, Winokur PL, Turley CB, Rupp RE, Hill H, Wolff M, Noah DL, Ross AC, Cress G, Belshe RB.

J Infect Dis. 2012 Sep 15;206(6):828-37. doi: 10.1093/infdis/jis445. Epub 2012 Jul 16.

2.

Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.

Frey SE, Bernstein DI, Brady RC, Keitel WA, El Sahly H, Rouphael NG, Mulligan MJ, Atmar RL, Edupuganti S, Patel SM, Dickey M, Graham I, Anderson EL, Noah DL, Hill H, Wolff M, Belshe RB.

Vaccine. 2015 Jan 1;33(1):163-73. doi: 10.1016/j.vaccine.2014.10.083. Epub 2014 Nov 11.

3.

Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?

Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.

Pediatrics. 2006 Sep;118(3):e570-8.

PMID:
16950948
4.

Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.

Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.

Pediatrics. 2006 Sep;118(3):e579-85.

PMID:
16950949
5.

Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.

Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.

Pediatr Infect Dis J. 2012 May;31(5):494-500. doi: 10.1097/INF.0b013e31824bb179.

PMID:
22301476
6.

A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.

de Whalley P, Walker W, Snape MD, Oeser C, Casey M, Moulsdale P, Harrill C, Andrews N, Hoschler K, Thompson B, Jones C, Chalk J, Kerridge S, Tomlinson R, Heath PT, Finn A, Faust S, Miller E, Pollard AJ.

Health Technol Assess. 2011 Dec;15(45):v-vi, xi-xiii, 1-128. doi: 10.3310/hta15450.

7.

A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.

Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.

J Infect Dis. 2013 Jun 15;207(12):1878-87. doi: 10.1093/infdis/jit091. Epub 2013 Mar 7.

8.

Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.

Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, Sauvageau C, Dionne M, Gilca R, Skowronski D.

Vaccine. 2011 Dec 9;30(1):35-41. doi: 10.1016/j.vaccine.2011.10.062. Epub 2011 Nov 7.

PMID:
22063386
9.

Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.

Vesikari T, Forstén A, Arora A, Tsai T, Clemens R.

Hum Vaccin Immunother. 2015;11(8):2102-12. doi: 10.1080/21645515.2015.1044167.

10.

Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.

Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, McNeil S, Dobson S, Kellner JD, Kuhn S, Kollman T, MacKinnon-Cameron D, Smith B, Li Y, Halperin SA.

Vaccine. 2012 May 14;30(23):3389-94. doi: 10.1016/j.vaccine.2012.03.046. Epub 2012 Mar 30.

PMID:
22469860
11.

H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study.

Walker WT, de Whalley P, Andrews N, Oeser C, Casey M, Michaelis L, Hoschler K, Harrill C, Moulsdale P, Thompson B, Jones C, Chalk J, Kerridge S, John TM, Okike I, Ladhani S, Tomlinson R, Heath PT, Miller E, Faust SN, Snape MD, Finn A, Pollard AJ.

Clin Infect Dis. 2012 Mar 1;54(5):661-9. doi: 10.1093/cid/cir905. Epub 2012 Jan 19.

12.

Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.

Bai Y, Shi N, Lu Q, Yang L, Wang Z, Li L, Han H, Zheng D, Luo F, Zhang Z, Ai X.

Hum Vaccin Immunother. 2015;11(7):1648-53. doi: 10.1080/21645515.2015.1037998.

13.

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.

Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.

BMC Infect Dis. 2013 Jul 24;13:343. doi: 10.1186/1471-2334-13-343.

14.

Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study.

McVernon J, Laurie K, Barr I, Kelso A, Skeljo M, Nolan T.

Influenza Other Respir Viruses. 2011 Jan;5(1):7-11. doi: 10.1111/j.1750-2659.2010.00172.x. Epub 2010 Aug 24.

15.

Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.

Ottóffy G, Horváth P, Muth L, Sólyom A, Garami M, Kovács G, Nyári T, Molnár D, Pauler G, Jankovics I.

Pediatr Blood Cancer. 2014 Jun;61(6):1013-6. doi: 10.1002/pbc.24893. Epub 2014 Jan 3.

PMID:
24395342
16.

The effect of age and recent influenza vaccination history on the immunogenicity and efficacy of 2009-10 seasonal trivalent inactivated influenza vaccination in children.

Ng S, Ip DK, Fang VJ, Chan KH, Chiu SS, Leung GM, Peiris JS, Cowling BJ.

PLoS One. 2013;8(3):e59077. doi: 10.1371/journal.pone.0059077. Epub 2013 Mar 12.

17.

Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.

Frenck RW Jr, Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, Hay CM, Dekker CL, Walter EB Jr, Cate TR, Edwards KM, Hill H, Wolff M, Leduc T, Tornieporth N.

Vaccine. 2011 Aug 5;29(34):5666-74. doi: 10.1016/j.vaccine.2011.06.010. Epub 2011 Jun 23.

18.

Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.

Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, Reisinger EC.

PLoS One. 2013 Aug 16;8(8):e70866. doi: 10.1371/journal.pone.0070866. eCollection 2013.

19.

Immunogenicity and safety of three 2010-2011 seasonal trivalent influenza vaccines in Chinese toddlers, children and older adults: a double-blind and randomized trial.

Luo FJ, Yang LQ, Ai X, Bai YH, Wu J, Li SM, Zhang Z, Lu M, Li L, Wang ZY, Shi NM.

Hum Vaccin Immunother. 2013 Aug;9(8):1725-34. doi: 10.4161/hv.24832. Epub 2013 Jun 4.

20.

Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6-35 months: a randomized, double-blind, controlled phase I clinical trial.

Li YP, Li W, Liang XF, Liu Y, Huang XC, Li CG, Li RC, Wang JZ, Wang HQ, Yin WD.

Influenza Other Respir Viruses. 2013 Nov;7(6):1297-307. doi: 10.1111/irv.12028. Epub 2012 Nov 8.

Supplemental Content

Support Center